Connect with us

Technology

Research In Motion Ltd (NASDAQ:BBRY) Z10 Smartphone On High Demand

Published

on

In UK and Canada stock-out for the Research In Motion Ltd(NASDAQ:BBRY) or Blackberry Z10 Smartphone were reported. There was limited supply of the Smartphone. BlackBerry’s Z10 is outselling the iPhone 5 and the Galaxy S III at a major Canadian retailer and BGR confirmed an important indicator of BlackBerry’s early success, half of BlackBerry Z10 sales in Canada and one-third of UK sales have been made to users coming from other platforms.

Moreover, 50% of pre- registration for the Z10 in Canada came from users who did not already own BlackBerry devices. It was unclear whether Z10 would be able to get the buyers over iPhone and Android users following its release.

BGR has now learned from multiple trusted sources that BlackBerry has indeed managed to pull off the coup it so desperately needed. Several high-level BlackBerry executives have confirmed internally that half of all BlackBerry Z10 sales in Canada have been made to new customers coming from other platforms. Even more, one-third of Z10 sales in the UK, another key market for BlackBerry, have been made to customers who did not already own BlackBerry smartphones.

On the said reports, BlackBerry refused to give any comment. Early reviewers worried that while BlackBerry 10 showed great promise and the Z10 was a terrific early effort, the new operating system didn’t offer any compelling differentiation that might draw users away from the iPhone and Android smartphones. If early performance in these two key markets is any indication, however, BlackBerry’s new platform may be a bigger draw than as expected.

Technology

Big Movers: Merrimack Pharmaceuticals Inc(NASDAQ:MACK), Keryx Biopharmaceuticals (NASDAQ:KERX), Array Biopharma Inc (NASDAQ:ARRY)

Published

on

Lakeway, NY — (MARKET NEWS CALL) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Array Biopharma Inc (NASDAQ:ARRY), Merrimack Pharmaceuticals Inc(NASDAQ:MACK), Keryx Biopharmaceuticals (NASDAQ:KERX).

Array Biopharma Inc (NASDAQ:ARRY)’s shares decreased 0.86% to $4.59. The company on Dec. 3 announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials.  This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties.

Should Investors Buy ARRY After The Recent Development? Find Out Here

Merrimack Pharmaceuticals Inc(NASDAQ:MACK)’s shares gained 2.02% to $10.08. The company on Dec. 12 announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in San Antonio, TX. Presentations include preclinical research and clinical data on MM-398, MM-302 and MM-121.

Is MACK Going To Rise or Fall After Today’s Price Action? Find Out Here

Presentations on Merrimack’s nanoliposomal platform include an abstract detailing clinical data from a cohort of ER/PR-positive metastatic breast patients treated with MM-398, a nanoliposomal encapsulation of irinotecan, in a cross-indication translational study investigating potential predictive response markers for MM-398 therapy.

Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares fell 1.17% to $13.57. The company on Dec. 4 announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2, 2014. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate having a BET active surface area greater than about 16 sq. m/g. The patent also claims a broad category of orally administrable forms covering Auryxia, as well as other oral formulations that could be developed in the future.

Can Traders Buy KERX After The Solid Rally? Get Free Trend Analysis Here

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.

Continue Reading

Technology

Traders Favroite: Advanced Micro Devices, Inc. (NYSE:AMD), DryShips, Inc. (NASDAQ:DRYS), Plug Power Inc. (NASDAQ:PLUG)

Published

on

Lakeway, NY — (US MARKET BUZZ) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Advanced Micro Devices, Inc. (NYSE:AMD), DryShips, Inc. (NASDAQ:DRYS), Plug Power Inc. (NASDAQ:PLUG).

Advanced Micro Devices, Inc. (NYSE:AMD)’s shares fell 0.81% to $2.46. The company announced that President and CEO Dr. Lisa Su will present at the J.P. Morgan 13th Annual Tech Forum at International CES on Tuesday, January 6, 2015 at 2:25 p.m. PST in Las Vegas.

Should Investors Buy AMD After The Recent Development? Find Out Here

Additionally, the company on Dec. 15 announced James A. Clifford (69) has joined the company as senior vice president of Global Operations, reporting to President and CEO Dr. Lisa Su. Clifford will be responsible for overseeing all aspects of AMD’s end-to-end manufacturing and supply chain strategy.

DryShips, Inc. (NASDAQ:DRYS)’s shares decreased 1.35% to $0.80. The company on Dec. 1 announced that it has repaid all remaining principal and interest of its 5% Convertible Notes due 2014, in accordance with the terms of the notes and the indenture governing the notes.

Is DRYS Going To Rise or Fall After Today’s Price Action? Find Out Here

Additionally, the company on Dec. 1 also announced that its 2014 Annual General Meeting of Shareholders, scheduled for, and convened on December 1, 2014, was adjourned due to lack of requisite quorum. The Company has set a new record date of Nov. 4, 2014 and only shareholders as of Nov. 4, 2014 are entitled to and are being requested to vote at the Meeting in person or by proxy.

Plug Power Inc. (NASDAQ:PLUG)’s shares declined 1.44% to $2.73. The company on Dec. 16 announced that it has been named to the 2014 Food Logistics FL100+ list. Food Logistics is the only publication dedicated exclusively to the global food and beverage supply chain. The publication’s 11th annual FL100+ list profiles innovative technology and software providers who influence the global food and beverage supply chains.

Can Traders Buy PLUG After The Solid Rally? Get Free Trend Analysis Here

Additionally, the company on Dec. 4 announced that it has executed a multi-year contract for its ReliOn integrated fuel cell solution and GenFuel hydrogen services to be used with a major North American telecommunications provider.

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.

Continue Reading

Technology

Special News: VIVUS, Inc. (NASDAQ:VVUS), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Idenix Pharmaceuticals Inc (NASDAQ:IDIX)

Published

on

VIVUS, Inc. (NASDAQ:VVUS)’s shares jumped 0.62% to $4.86. The company on June 12 announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.

Get the Inside Scoop On VVUS here with this Free Report

The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Qsymia® (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents 7,056,890, 7,553,818, 7,659,256, 7,674,776, 8,580,298, and 8,580,299, which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. VIVUS filed the lawsuit on the basis that Actavis’s proposed generic products infringe each of these patents held by VIVUS.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares decreased 0.23% to $4.40. The 52 week trading range for the company is $3.70 – $7.85. The company is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development.

You won’t believe what we found out about SNTA

Idenix Pharmaceuticals Inc (NASDAQ:IDIX)’s shares gained 0.84% to $24.06. The securities litigation law firm of Brower Piven, A Professional Corporation, on June 16 has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals, Inc. (IDIX) and other violations of state law by the board of directors of Merck & Co., Inc. (“Merck”), in a transaction valued at approximately $3.85 billion. Under the terms of the transaction, shareholders of Idenix would receive $24.50 in cash for each share of Idenix they own.

Why Should You Buy IDIX Now? Get The Free Trend Analysis Here

Continue Reading
Advertisement

Trending